

## Devyser wins tender for oncology NGS solutions in Italy

**Devyser was awarded a tender in Italy for some of its oncology NGS solutions. The tender with the University Hospital of Bologna is valid for two years with the potential of a one-year extension. The indicative order value of the tender is estimated to be up to 5.5 million SEK.**

"We are delighted to win this tender for our competitive oncology NGS solutions," says Fredrik Alpsten, Devyser CEO. "Hereditary cancer detection and treatment is one of our strategic focus areas. We launched two new products within this area during the last year. This tender demonstrates that laboratories truly appreciate the simplicity and quality of our solutions. These tests are important, as they are used to understand mutations associated with increased cancer risks, to provide more personalized care, and enable preventive measures, ultimately saving lives."

**For more information, please contact:**

Fredrik Alpsten, CEO

E-mail: [fredrik.alpsten@devyser.com](mailto:fredrik.alpsten@devyser.com)

Telephone: +46 70 667 31 06

Theis Kipling, CCO

E-mail: [theis.kipling@devyser.com](mailto:theis.kipling@devyser.com)

Telephone: +46 73 598 07 76

### **About Devyser**

Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.

For more information, visit [www.devyser.com](http://www.devyser.com).